High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae
| Autor: | Anna Ribera, Julian Gomez, Francesc Marco, Josep M. Sierra, Joaquim Ruiz, Margarita M. Navia, Jordi Vila, Josep Mensa |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Microbiology (medical)
Nalidixic acid Microbial Sensitivity Tests Drug resistance medicine.disease_cause Microbiology Nalidixic Acid Anti-Infective Agents Ciprofloxacin Escherichia coli medicine Humans chemistry.chemical_classification biology Drug Resistance Microbial General Medicine biology.organism_classification Virology Enterobacteriaceae Amino acid Phenotype Infectious Diseases chemistry DNA Gyrase Mutation Microbial genetics Bacteria medicine.drug |
| Zdroj: | Diagnostic Microbiology and Infectious Disease. 42:257-261 |
| ISSN: | 0732-8893 |
| Popis: | Therapeutic failure of infections during their treatment with quinolones has been often described. This may be due to the development of resistance during treatment of an infecting strain which already had diminished susceptibility to quinolones, even though the initial MIC did not exceed the breakpoint. In this study the prevalence of the nalidixic acid resistant, ciprofloxacin susceptible phenotype among Enterobacteriaceae was analyzed. The results showed that 113 out of 151 (74.83%) strains of the Enterobacteriaceae with diminished susceptibility to ciprofloxacin (MICs from 0.06 to 1 microg/ml) were resistant to nalidixic acid (MICs32 microg/ml). The Escherichia coli strains presenting this phenotype already have a mutation in the amino acid codon Ser-83 of the gyrA gene, so that the possibility of developing a second mechanism of resistance during treatment is very high. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect